Related Experiment Video

Updated: Aug 13, 2025

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.2K

BLyS/APRIL dual inhibition for IgG4-RD: a prospective single-arm clinical trial of telitacicept

Shaozhe Cai1, Ziwei Hu1, Yu Chen1

  • 1Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

Annals of the Rheumatic Diseases
|January 19, 2023
PubMed
Abstract

No abstract available in PubMed .

Keywords:
Autoimmune DiseasesB-LymphocytesGlucocorticoids

More Related Videos

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.1K
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

6.9K

Related Experiment Videos

Last Updated: Aug 13, 2025

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.2K
Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.1K
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

6.9K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

205
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
205
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

234
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
234

Articles linked to this work by shared authors, journal, and citation graph.

Pirfenidone combined with nintedanib in connective tissue disease - associated interstitial lung disease with radiologic progression during antifibrotic monotherapy: A case series.

Clinical rheumatology·2026

Multimetal-Doped Nanoenzymes Reprogram Macrophages for Immunotherapy of Gouty Arthritis.

Advanced healthcare materials·2026

Invasive aspergillosis in autoimmune inflammatory rheumatic diseases: epidemiology, risk factors, diagnosis, management and challenges.

Annals of medicine·2026

CCR2-Guided Treg Exosome-Gas6 Hybrid Synergistically Reprograms Macrophage Inflammation and Immune Tolerance in Gouty Arthritis.

Advanced healthcare materials·2026

Extracellular HMGB1 impairs macrophage phagocytosis and promotes salivary gland dysfunction in Sjogren's syndrome.

Journal of immunology (Baltimore, Md. : 1950)·2025

Evaluation of MRI-based brain oxygen extraction fraction mapping in patients with systemic lupus erythematosus.

Lupus science & medicine·2025

The ASAS core set for the assessment of axial spondyloarthritis in clinical practice.

Annals of the rheumatic diseases·2026

Ten-year outcomes after treat-to-target therapy in early rheumatoid arthritis.

Annals of the rheumatic diseases·2026

Multiomics landscape of systemic sclerosis: from autoantibody-positivity to established disease.

Annals of the rheumatic diseases·2026

IgG4-related disease is not associated with an increased incidence of malignancy in a large, single-centre cohort.

Annals of the rheumatic diseases·2026

Early arthritis signs and symptoms revisited-is synovitis what we are assessing?

Annals of the rheumatic diseases·2026

Preclinical and clinical outcomes in patients with high rheumatoid factor levels treated with TNF inhibitors:a systematic review.

Annals of the rheumatic diseases·2026

Refractory Anti-HMGCR Necrotizing Myopathy With Progressive Hypercapnic Respiratory Failure Responsive to a JAK Inhibitor.

Case reports in rheumatology·2026

Type I interferon upregulates IL-18RAP in neutrophils to enhance chemotaxis and bactericidal activity in autoimmune liver diseases.

Journal of translational autoimmunity·2026

Primary ocular adnexal MALT lymphoma involving the upper eyelid in a young woman: a case report and literature review.

Frontiers in immunology·2026

Efficacy and safety of intravenous immunoglobulin in systemic sclerosis: a systematic review and meta-analysis.

Frontiers in immunology·2026

High EBV-reactive IgG levels in serum are linked to typical inflammatory cerebrospinal fluid features in multiple sclerosis.

Frontiers in immunology·2026

Isolated Left Innominate Artery with a Right Arch and Bilateral Patent Arterial Ducts in a Patient with 22q11 Microdeletion: Report of a Rare Case.

Journal of cardiovascular and thoracic research·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us